BioSpace News Archive

To suggest that the pharma industry is a reluctant partner in President Donald Trump’s attempts to decrease drug prices is to overstate the fact. But now the industry appears to be pushing back, at least a little bit.

Nearly two weeks after the U.S. Food and Drug Administration approved Sanofi and Regeneron’s Dupixent as an add-on maintenance therapy for moderate to severe asthma, the France-based company reported a surge in sales for the medication in its most recent quarterly report.

Noting advances in genetic manipulation and gene editing, the Food and Drug Administration announced a new Plant and Animal Biotechnology Innovation Action Plan.

Adagene, Inc. today announced the dosing of its first patient in its Phase I trial in American for its lead product ADG-106, a fully human agonistic monoclonal antibody (mAb) targeting a novel epitope of CD137.

Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces the results for the third quarter 2018. Total revenues grew 45 per cent compared with Q3 2017 (34 per cent at constant exchange rates (CER)) and amounted to SEK 2,315 M. EBITA was SEK 933 M, an increase of 74 per cent for the quarter, and gross margin amounted to 75 per cent.

Achieve Life Sciences, Inc. today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018.

Industry Experts Offer Insight for Individuals Diagnosed with Late-Stage Illness

United Therapeutics Corporation today announced its financial results for the quarter ended September 30, 2018.

Ophthotech Enters into Second Series of Gene Therapy Agreements with the University of Pennsylvania and the University of Florida for Exclusive Option for Novel Product Candidates to Treat Best Disease

CytoSorbents Corporation will report Q3 2018 financial results after the market close on Tuesday, November 6, 2018.